Skip to main content
Supernus' partial-onset seizure monotherapy gets FDA nod

Supernus Pharmaceuticals received approval from the FDA to market its Oxtellar XR, or oxcarbazepine, extended-release tablets as a monotherapy for patients age 6 and older who have partial-onset seizures. The drug was previously approved as adjunctive treatment for the same indication.

Full Story: